Phase II trial of piperazinedione (NCS 135758) in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.

@article{Thigpen1983PhaseIT,
  title={Phase II trial of piperazinedione (NCS 135758) in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.},
  author={J. Tate Thigpen and John A. Blessing and Howard D. Homesley and Leon L. Adcock},
  journal={American journal of clinical oncology},
  year={1983},
  volume={6 4},
  pages={423-6}
}
Thirty-eight patients with advanced or recurrent squamous cell carcinoma of the cervix no longer amenable to management with surgery and/or radiotherapy were given piperazinedione 9 mg/m2 intravenously every 3 weeks. Five (13%) experienced either complete or partial regression of disease, while 13 (34%) demonstrated stable disease. Responses were relatively… CONTINUE READING